Market Data
Market Cap₹167.32 Cr.
52W High₹143.6
Current Price₹56.8
52W Low₹36.9
Down from 52W High60.4 %
Face Value₹10
Performance
ROCE10.74 %
ROE10.77 %
EPS (TTM)₹-0.61
EPS Prev Qtr₹0.52
EPS Last Year₹2.71
EBITDA Qtr₹1.45 Cr.
Book Value₹42
Financial Health
Debt/Equity0.06
Debt/Profit0.55
Total Assets₹148.174 Cr.
Promoter Holding52.62 %
Earning Power2.83 %
Valuation
Stock P/E12.65
Industry P/E33.81
Price to Book1.36
Price to Sales2.01
Graham Number₹64.96
Key Metrics
__derived
1
Face Value
₹10
About Brooks Laboratories Ltd
Healthcare · Pharmaceuticals
Brooks Laboratories Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹167.32 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a manageable debt-to-equity ratio of 0.06, indicating low financial risk.
- The Return on Equity (ROE) of 10.77% shows efficient use of shareholder equity to generate profits.
- The Return on Capital Employed (ROCE) of 10.74% reflects solid operational efficiency in generating returns from capital.
Weaknesses
- The company has a relatively high P/E ratio of 15.48, which may indicate that the stock is overvalued compared to peers.
- The P/B ratio of 1.67 suggests that the market values the company at a premium to its book value.
- The company does not currently offer a dividend yield, which may be a concern for income-focused investors.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
📊 Jun 2026: Revenue fell 10.0% YoY, Profit fell 118.7% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 25.51 | 23.45 | 16.57 | 20.21 | 22.96 |
| ↳ QoQ Growth | - | -8.1% | -29.3% | +22.0% | +13.6% |
| Expenses | 22.78 | 21.32 | 16.23 | 19.94 | 21.51 |
| Operating Profit | 2.74 | 2.13 | 0.34 | 0.27 | 1.45 |
| OPM % | 10.74% | 9.08% | 2.05% | 1.34% | 6.32% |
| Other Income | 0.22 | 0.39 | 0.13 | 0.44 | 0.18 |
| Interest | 0.3 | 0.28 | 0.16 | 0.09 | 0.21 |
| Depreciation | 0.39 | 0.39 | 0.39 | 0.41 | 0.42 |
| EBITDA | 3.13 | 2.52 | 0.73 | 0.68 | 1.87 |
| EBITDA Margin % | 12.27% | 10.75% | 4.41% | 3.36% | 8.14% |
| Profit Before Tax | 9.58 | 7.98 | 5.5 | 1.52 | -1.79 |
| Tax % | 0% | 0% | 0% | 0% | 0% |
| Net Profit | 9.58 | 7.98 | 5.5 | 1.52 | -1.79 |
| ↳ QoQ Growth | - | -16.7% | -31.1% | -72.4% | -217.8% |
| EPS | 3.25 | 2.71 | 1.87 | 0.52 | -0.61 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 85.74 | 83.19 |
| Expenses | 80.27 | 79 |
| Operating Profit | 5.48 | 4.19 |
| OPM % | 6.39% | 5.04% |
| Other Income | 1.18 | 1.14 |
| Interest | 0.83 | 0.74 |
| Depreciation | 1.58 | 1.61 |
| Profit Before Tax | 24.58 | 13.21 |
| Tax % | 0% | 0% |
| Net Profit | 24.58 | 13.21 |
| EPS | 8.35 | 4.49 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
-57.93%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
10.77%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 29.46 | 29.4572 |
| Reserves | 68.65 | 93.1999 |
| Borrowings | 7.58 | 7.28 |
| Other Liabilities | 18 | 18.24 |
| Total Liabilities | 123.69 | 148.1739 |
| Fixed Assets | 13.97 | 14.5188 |
| CWIP | 0 | 1.1906 |
| Investments | 73.55 | 92.34 |
| Other Assets | 36.17 | 40.12 |
| Total Assets | 123.69 | 148.1739 |
Cash Flows
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity | 2.6263 | 9.2934 |
| Cash from Investing Activity | -45.1352 | -2.9198 |
| Cash from Financing Activity | 42.4268 | 0.1709 |
| Net Cash Flow | -0.0821 | 6.5445 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 599.79 |
| ROCE % | 3.89% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 52.62% | 52.62% | 52.62% | 52.62% |
| FIIs % | 0.01% | 0.09% | 0.17% | 0% |
| DIIs % | 10.38% | 10.38% | 10.38% | 10.38% |
| Public % | 31.7% | 31.84% | 31.56% | 30.73% |
| No. of Shareholders | 10,078 | 10,532 | 10,741 | 11,161 |
Major Shareholders (>1%)
- Atul RanchalPromoter and Promoter Group19.24%
- Rajesh MahajanPromoter and Promoter Group17.36%
- Quant Mutual Fund - Quant Business Cycle FundPublic Shareholding9.90%
- Erwin MahajanPromoter and Promoter Group4.10%
As of 2026-06-30View all shareholders →